hupo2017@conferencepartners.ie

Dobrin Nedelkov

Dobrin Nedelkov, Isoformix Inc., Tempe, AZ, USA

Talk Title:

Translating MS protein assays into the clinic: The challenging road ahead, and the potential of posttranslationally modified proteins as new biomarker targets for clinical MS protein tests

Bio:

Dr. Nedelkov received a Ph.D. in Chemistry and Biochemistry from Arizona State University in 1997. After spending a year as a Postdoctoral Associate at Yale University, Dr. Nedelkov joined Intrinsic Bioprobes where over the span of 15 years he progressed through the ranks to ultimately become Scientific Director and CEO of the company, leading the early commercialization efforts in technology development for targeted proteomics and protein biomarkers. In 2013 he joined the Biodesign Institute at Arizona State University, serving as a group leader of the Molecular Biomarkers laboratory, focusing on proteoform biomarker discovery, validation, and translation. In 2017 Dr. Nedelkov started Isoformix with the goal of translating MS protein tests into the clinic.
Dr. Nedelkov has authored over 100 peer reviewed scientific articles, presented at more than 60 scientific meetings, has 4 issued patents, and has served as a principal investigator on numerous NIH grants.

Abstract:

Protein MS assays are forecasted to be the next-generation tests for precise and enabling measurement of clinical protein biomarkers. But in the 30 years since the MALDI and ESI MS invention, only a dozen protein MS tests have been translated into clinical laboratories. Analytical performance requirements have been in place for some time, along with small molecules MS clinical tests precedents, so it seems that key clinical and economic drivers have not been met for their adoption. Even when MS approaches result in new protein biomarkers discovery, enzymatic immunoassays oftentimes replace MS in clinical lab tests. One way to drive translation and adoption of MS protein tests is to target protein features that could only be detected with MS – such as post-translational modifications (PTMs) – thus generating both content and demand. Discussed in this presentation will be some viable PTM protein targets and the path forward for these clinical MS protein tests.

image1